Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70490 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Shiva Poola und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Brody School of Medicine, East Carolina University/ECU Health Medical C…. Hauptthemen laut MEDLINE: Rituximab, Virus Activation, Hepatitis B Antibodies, Hepatitis B virus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti‐CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti‐HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti‐HBs) titer have a higher level of protection against reactivation.
Aim
The purpose of this study was to systematically review the role of anti‐HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.
Methods
We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolved HBV infection, defined as HBsAg negative and anti‐HBc positive, which discussed anti‐HBs titer. The search was conducted in PubMed, Embase via Elsevier, Scopus, and Cochrane CENTRAL inclusive July 2025. We evaluated the incidence of HBV reactivation from cohort studies that described anti‐HBs categorically based on anti‐HBs titer: ‘negative’ (titer < 10 iU/L), ‘10–100 iU/L’, or ‘> 100 iU/L’. Meta‐analysis statistics describe the proportion and risk difference for different anti‐HBs levels.
Results
The overall reactivation rate was 12.6%. There was a significant difference in HBV reactivation depending on titer: anti‐HBs negative 27.3% (51/195) (20.0%–36.0%), titer < 100 iU/L 13.8% (47/379) (8.8%–20.8%), and titer > 100 iU/L 3.5% (8/339) (1.8%–6.9%).
Conclusions
Those with anti‐HBs titer > 100 iU/L can be considered lower risk for HBV reactivation and may not require antiviral therapy, but monitoring with initiation of antiviral therapy if titer falls below 100 iU/L.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Brody School of Medicine, East Carolina University/ECU Health Medical Center, Greenville, North Carolina, USA.
- Research Librarian for the Health Sciences, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.
- Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.
ORCID-Profile: Kerry Sewell
Zitieren
APA
Poola, S., Kratzer, M., Sewell, K., Yang, Z., & Tillmann, H. L. (2026). Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70490
Vancouver
Poola S, Kratzer M, Sewell K, Yang Z, Tillmann HL. Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70490
BibTeX
@article{Poola2026,
author = {Poola, Shiva and Kratzer, MaryKate and Sewell, Kerry and Yang, Zikun and Tillmann, Hans L},
title = {Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70490}
}
EUVIMED